Emergent BioSolutions Inc. (EBS) forty fourth Annual J.P. Morgan Healthcare Convention January 14, 2026 8:15 PM EST
Firm Members
Joseph Papa – CEO, President & Director
Richard Lindahl – Govt VP & CFO
Convention Name Members
Jessica Fye – JPMorgan Chase & Co, Analysis Division
Presentation
Jessica Fye
JPMorgan Chase & Co, Analysis Division
Nice. Welcome, everybody. My identify is Jess Fye. I am a biotech analyst at JPMorgan. And we’re persevering with our forty fourth Annual Healthcare Convention as we speak with Emergent.
First, you are going to hear a presentation from the corporate, after which we will have some Q&A. So for these of you within the room, if you wish to ask a query, simply increase your hand, somebody will convey you a microphone for the webcast. And alternatively, for these listening on-line, you possibly can submit questions by way of the portal, and I can learn them off the iPad up right here. So with that out of the way in which, let me go it over to Emergent’s CEO, Joe Papa.
Joseph Papa
CEO, President & Director
Thanks. Good afternoon, everybody. Welcome to the Emergent presentation. It is my pleasure to speak to these of you right here as we speak within the room and people on the webcast. Emergent is a 25-year-old firm. Our mission is to guard and save lives. Now we have — in 2024, began a multiyear turnaround plan. And it is my pleasure as we speak to replace you on our progress of the place we’re with that turnaround plan and simply what we see for the longer term.
So let me go to the — that is simply our protected harbor assertion. So I will be making some feedback as we speak that I will refer you to our SEC filings for any extra data and danger elements for you.
So what’s the overview of Emergent? Emergent is an organization, as I discussed, 25 years
